433 related articles for article (PubMed ID: 33575314)
1. Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Ding L; Hu Y; Huang H
Stem Cell Investig; 2021; 8():1. PubMed ID: 33575314
[TBL] [Abstract][Full Text] [Related]
2. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
Mishra AK; Gupta A; Dagar G; Das D; Chakraborty A; Haque S; Prasad CP; Singh A; Bhat AA; Macha MA; Benali M; Saini KS; Previs RA; Saini D; Saha D; Dutta P; Bhatnagar AR; Darswal M; Shankar A; Singh M
Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006053
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S
Front Immunol; 2019; 10():1613. PubMed ID: 31379824
[TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy for multiple myeloma: state of the art and prospects.
van de Donk NWCJ; Usmani SZ; Yong K
Lancet Haematol; 2021 Jun; 8(6):e446-e461. PubMed ID: 34048683
[TBL] [Abstract][Full Text] [Related]
5. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
6. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
7. Hematologic Malignancies: Plasma Cell Disorders.
Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
[TBL] [Abstract][Full Text] [Related]
8. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.
Rosenzweig M; Urak R; Walter M; Lim L; Sanchez JF; Krishnan A; Forman S; Wang X
Cytotherapy; 2017 Jul; 19(7):861-866. PubMed ID: 28483281
[TBL] [Abstract][Full Text] [Related]
9. CAR T cells targeting options in the fight against multiple myeloma.
Nicolini F; Bravaccini S; Mazza M; Gruszka AM; Tazzari M; MartÍn-Antonio B; Juan M; Ibrahim T; Maltoni R; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):37-45. PubMed ID: 32955187
[TBL] [Abstract][Full Text] [Related]
10. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
[TBL] [Abstract][Full Text] [Related]
11. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
12. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
13. IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model.
Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa AR; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce JA; Bogen B; James SE; van den Brink MRM
Blood; 2024 Apr; ():. PubMed ID: 38579288
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
15. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z; Zhang Y; Wang X
Biomark Res; 2021 Jul; 9(1):58. PubMed ID: 34256851
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
17. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
18. [Clinical development of CAR-T therapy for refractory multiple myeloma].
Ohmine K
Rinsho Ketsueki; 2018; 59(8):1058-1065. PubMed ID: 30185706
[TBL] [Abstract][Full Text] [Related]
19. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
[TBL] [Abstract][Full Text] [Related]
20. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
